Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)
This study has been completed.
Study NCT00600119   Information provided by AstraZeneca

First Received on January 11, 2008.   Last Updated on January 28, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Opioid Induced Constipation (OIC)
Additional conditions recognized in this trial
Constipation
More general conditions related to this trial
Signs and Symptoms
Signs and Symptoms, Digestive
Interventions listed in this trial
placebo
NKTR-118
Additional drug interventions recognized in this trial
Analgesics, Opioid
More general drug interventions related to this trial
Analgesics
Central Nervous System Agents
Central Nervous System Depressants
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
AstraZeneca
Nektar Therapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services